The Ebola virus break out in Western Africa dominated a lot of the stories in 2014. The highly catching pathogen spreads rapidly and kills over 50% of those people who get infected, resulting in heavy panics across multiple continents. While most of the dead are in Africa, health employees did bring the virus home to other states and continents.
For all the bad news and focus upon doomsday eventualities on what the virus could do, there are actually dome commercial benefits of Ebola virus flare-ups. The industrial benefits principally breakdown between non-profit or state groups and for-profit biotechnology firms.
Central authority or aid associations like the Red Cross or the CDC tend to see increases in funding in events such as these. The business benefits to them are direct and help out those on the ground suffering or assisting and containing an outburst.
This containment keeps commercial interruption when funding is acceptable to turn the tide of an outburst.
The longer-term commercial benefits of Ebola virus outbursts are biotech corporations working on vaccines or drugs that might improve survival rates of those infected by Ebola. One such firm is Tekmira, which has been given blessings by the FDA to expand testing on in its experimental Ebola drug for bigger scale clinical trials.
Sarepta Therapeutics, Nanoviricides and BioCryst Pharmaceuticals are other biotech outfits that would see increased business in the future if their own Ebola drugs and medicinal compounds turn out to be of worth.
While the 2014 Ebola break out is first to have caught global attention as much as it probably did, it was barely the first onset. Others have occurred, and more will occur in the future. Any business which has an Ebola drug or vaccine on the market that proves effective can be certain to see a rise in business in the future.
For all the bad news and focus upon doomsday eventualities on what the virus could do, there are actually dome commercial benefits of Ebola virus flare-ups. The industrial benefits principally breakdown between non-profit or state groups and for-profit biotechnology firms.
Central authority or aid associations like the Red Cross or the CDC tend to see increases in funding in events such as these. The business benefits to them are direct and help out those on the ground suffering or assisting and containing an outburst.
This containment keeps commercial interruption when funding is acceptable to turn the tide of an outburst.
The longer-term commercial benefits of Ebola virus outbursts are biotech corporations working on vaccines or drugs that might improve survival rates of those infected by Ebola. One such firm is Tekmira, which has been given blessings by the FDA to expand testing on in its experimental Ebola drug for bigger scale clinical trials.
Sarepta Therapeutics, Nanoviricides and BioCryst Pharmaceuticals are other biotech outfits that would see increased business in the future if their own Ebola drugs and medicinal compounds turn out to be of worth.
While the 2014 Ebola break out is first to have caught global attention as much as it probably did, it was barely the first onset. Others have occurred, and more will occur in the future. Any business which has an Ebola drug or vaccine on the market that proves effective can be certain to see a rise in business in the future.
About the Author:
my name is alfred obi i have been a biological scientist for years training people on ebola virus disease update and ebola virus disease that has affected most countries in africa be happy to come to my site for your free protective gear on ebola thanks.
No comments:
Post a Comment